Singapore-based Eywa Pharma raises $30m from Fidelity, F-Prime Capital Partners

Eywa is engaged in R&D, manufacture, marketing, sale and distribution of generic finished dosage formulations and provides affordable generic pharmaceuticals across the world.

Singapore-based generic pharmaceutical firm Eywa Pharma Pte Ltd has secured $30 million from a group of investors including Eight Roads Ventures India, the proprietary investment arm of FIL, Fidelity International Ltd, and the US-based F-Prime Capital Partners.

Continue reading this story with a subscription to DealStreetAsia.


Should your colleagues be reading this article too? Contact us for corporate subscriptions at